Detoxification of Gold Nanorods by Treatment with Polystyrenesulfonate
Source abstract
Abstract
We address an outstanding issue associated with the biocompatibility of gold nanorods (GNRs), a promising agent for biomedical imaging and theragnostics. GNRs are typically prepared in the presence of cetyltrimethylammonium bromide (CTAB), a cationic surfactant whose rigorous removal is necessary due to its cytotoxicity and membrane-compromising properties. CTAB-stabilized GNRs can be partially purified by treatment with polystyrenesulfonate (PSS), an anionic polyelectrolyte often used as a surrogate peptizing agent, followed by chloroform extraction and ultrafiltration with minimal loss of dispersion stability. However, in vitro cytotoxicity assays of PSS-coated GNRs revealed IC(50) values in the low to submicromolar range, with subsequent studies indicating the source of toxicity to be associated with a persistent PSS-CTAB complex. Further exchange of CTAB-laden PSS with fresh polyelectrolyte greatly improves biocompatibility, to the extent that 85 microg/mL of "CTAB-free" GNRs (the highest level evaluated) has comparable toxicity to a standard phosphate buffer solution. Ironically, PSS is not effective by itself at stabilizing GNRs in CTAB-depleted suspensions: while useful as a detergent for GNR detoxification, it should be replaced by more robust coatings for long-term stability under physiological conditions.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Gold and Silver Nanoparticles Synthesis and Applications · Nanoparticle-Based Drug Delivery · Biosensors and Analytical Detection
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, Purdue University, West Lafayette, Indiana 47907
Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland 21702
References (49)
Show source-provided references
1. Bentzen S. M. · Lancet Oncol. · 2005 · 6 · 11210.1016/S1470-2045(05)01737-7 ↗
2. Cuenca A. G. · Cancer · 2006 · 107 · 45910.1002/cncr.22035 ↗
3. Ozdemir V. · Nat. Biotechnol. · 2006 · 24 · 94210.1038/nbt0806-942 ↗
4. Huff T. B. · Nanomedicine · 2007 · 2 · 12510.2217/17435889.2.1.125 ↗
5. Tong L. · Adv. Mater. · 2007 · 19 · 313610.1002/adma.200701974 ↗
6. Huang X. · J. Am. Chem. Soc. · 2006 · 128 · 211510.1021/ja057254a ↗
7. Black K. C. · Mol. Imaging · 2008 · 7 · 5010.2310/7290.2008.0007 ↗
8. Pissuwan D. · J. Nanoparticle Res. · 2007 · 9 · 110910.1007/s11051-007-9212-z ↗
9. Pissuwan D. · Nano Lett. · 2007 · 7 · 380810.1021/nl072377+ ↗
10. Hirsch L. R. · Proc. Natl. Acad. Sci. U.S.A. · 2003 · 100 · 1354910.1073/pnas.2232479100 ↗
11. Gobin A. M. · Nano Lett. · 2007 · 7 · 192910.1021/nl070610y ↗
12. Chen J. · Nano Lett. · 2007 · 7 · 131810.1021/nl070345g ↗
13. Zharov V. P. · Biophys. J. · 2005 · 90 · 61910.1529/biophysj.105.061895 ↗
14. Zharov V. P. · Lasers Surg. Med. · 2005 · 37 · 21910.1002/lsm.20223 ↗
15. Cortesi R. · Int. J. Pharm. · 1996 · 139 · 6910.1016/0378-5173(96)04574-7 ↗
16. Mirska D. · Colloids Surf. B · 2005 · 40 · 5110.1016/j.colsurfb.2004.10.007 ↗
17. Takahashi H. · Langmuir · 2006 · 22 · 210.1021/la0520029 ↗
18. Connor E. E. · Small · 2005 · 1 · 32510.1002/smll.200400093 ↗
19. Huff T. B. · Langmuir · 2007 · 23 · 159610.1021/la062642r ↗
20. Hayat M. A. · 1989 · 1
21. Gole A. · Chem. Mater. · 2005 · 17 · 132510.1021/cm048297d ↗
22. Ding H. · J. Phys. Chem. C · 2007 · 111 · 1255210.1021/jp0733419 ↗
23. Kim K. · Appl. Phys. Lett. · 2007 · 90 · 22390110.1063/1.2743752 ↗
24. Durr N. J. · Nano Lett. · 2007 · 7 · 94110.1021/nl062962v ↗
25. Shepherd G. · J. Toxicol. Clin. Toxicol. · 2000 · 38 · 38910.1081/CLT-100100948 ↗
26. Nikoobakht B. · Chem. Mater. · 2003 · 15 · 195710.1021/cm020732l ↗
27. Sau T. K. · Langmuir · 2004 · 20 · 641410.1021/la049463z ↗
28. Zweifel D. A. · Chem. Mater. · 2005 · 17 · 425610.1021/cm0506858 ↗
29. Berr S. S. · J. Phys. Chem. · 1987 · 91 · 476010.1021/j100302a024 ↗
30. Introducing PSS prior to the first chloroform wash is less efficient and requires a greater amount of polyelectrolyte, due to the significant formation of soluble PSS−CTAB complex.
31. Chibowski S. · J. Colloid Interface Sci. · 1990 · 134 · 17410.1016/0021-9797(90)90264-O ↗
32. Hlady V. · J. Colloid Interface Sci. · 1982 · 87 · 39510.1016/0021-9797(82)90336-8 ↗
33. Ishigami A · Cell Tissue Res. · 2005 · 320 · 24310.1007/s00441-004-1073-5 ↗
34. Holmberg K. · 2003
35. Almgren M. · Langmuir · 1992 · 8 · 240510.1021/la00046a011 ↗
36. Maurdev G. · Langmuir · 2002 · 18 · 940110.1021/la0205349 ↗
37. Kogej K. · Langmuir · 1999 · 15 · 425110.1021/la9811517 ↗
38. Semchyschyn D. J. · Langmuir · 1996 · 12 · 25310.1021/la950244a ↗
39. Samokhina L. · Langmuir · 2007 · 23 · 361510.1021/la063178t ↗
40. Aslan K. · Langmuir · 2002 · 18 · 605910.1021/la025795x ↗
41. Dai Q. · Chem. Commun. · 2008 · 285810.1039/b804797a ↗
42. Liao H. · Chem. Mater. · 2005 · 17 · 463610.1021/cm050935k ↗
43. Niidome T. · J. Controlled Release · 2006 · 35 · 500
44. Zhao Y. · J. Am. Chem. Soc. · 2005 · 127 · 732810.1021/ja050432f ↗
45. Orendorff C. J. · J. Phys. Chem. B · 2006 · 110 · 399010.1021/jp0570972 ↗
46. Alley M. C. · Cancer Res. · 1988 · 48 · 589
47. Hansen M. B. · J. Immunol. Methods · 1989 · 119 · 20310.1016/0022-1759(89)90397-9 ↗
48. Decker T. · J. Immunol. Methods · 1988 · 15 · 6110.1016/0022-1759(88)90310-9 ↗
49. Korzeniewski C. · J. Immunol. Methods · 1983 · 64 · 31310.1016/0022-1759(83)90438-6 ↗